
    
      This is a long-term persistence study in which subjects who participated in the primary
      studies HAV-112 (208109/108) or HAV-123 (208109/114) and did not receive an additional dose
      of hepatitis A vaccine since then, will be invited to provide a blood sample at Years 21 to
      25 after their second vaccine dose. No vaccine will be administered during the study period.
    
  